{"product_id":"chonluten-20mg-vial","title":"Chonluten 20mg vial","description":"\u003cp data-start=\"122\" data-end=\"382\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"122\" data-end=\"382\"\u003e\u003cstrong data-start=\"122\" data-end=\"135\"\u003eChonluten\u003c\/strong\u003e is most consistently described in the peer-indexed Khavinson-peptide literature as a \u003cstrong data-start=\"221\" data-end=\"243\"\u003edefined tripeptide\u003c\/strong\u003e:\u003cbr data-start=\"244\" data-end=\"247\"\u003e\u003cstrong data-start=\"247\" data-end=\"268\"\u003eGlu–Asp–Gly (EDG)\u003c\/strong\u003e, positioned as a \u003cstrong data-start=\"286\" data-end=\"343\"\u003erespiratory\/lung (bronchopulmonary tree) bioregulator\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"384\" data-end=\"804\"\u003e\u003cstrong data-start=\"384\" data-end=\"435\"\u003eCritical identity caveat (marketplace reality):\u003c\/strong\u003e In commercial channels, “Chonluten” is sometimes sold as a \u003cstrong data-start=\"495\" data-end=\"514\"\u003epeptide complex\u003c\/strong\u003e (e.g., “AC-7”) or even presented as “amino acids listed on the label,” which can blur whether the product is \u003cstrong data-start=\"624\" data-end=\"636\"\u003epure EDG\u003c\/strong\u003e or a \u003cstrong data-start=\"642\" data-end=\"653\"\u003emixture\u003c\/strong\u003e. Always treat “Chonluten” as a \u003cem data-start=\"685\" data-end=\"697\"\u003ebrand name\u003c\/em\u003e unless you have \u003cstrong data-start=\"714\" data-end=\"731\"\u003eCOA + MS\/HPLC\u003c\/strong\u003e confirming EDG content and purity. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"806\" data-end=\"809\"\u003e\n\u003ch3 data-start=\"811\" data-end=\"862\"\u003e2) Biological rationale: why a lung tripeptide?\u003c\/h3\u003e\n\u003cp data-start=\"863\" data-end=\"1187\"\u003eThe \u003cstrong data-start=\"867\" data-end=\"902\"\u003eultrashort peptide bioregulator\u003c\/strong\u003e hypothesis proposes that 2–4 amino-acid peptides can modulate \u003cstrong data-start=\"965\" data-end=\"1006\"\u003ecell phenotype and tissue homeostasis\u003c\/strong\u003e by influencing \u003cstrong data-start=\"1022\" data-end=\"1050\"\u003egene-expression programs\u003c\/strong\u003e, potentially through direct\/indirect interactions with DNA\/chromatin and transcriptional networks. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"1189\" data-end=\"1285\"\u003eFor Chonluten (EDG), the claimed “organ specificity” is lung\/bronchial mucosa, with emphasis on:\u003c\/p\u003e\n\u003cul data-start=\"1286\" data-end=\"1475\"\u003e\n\u003cli data-start=\"1286\" data-end=\"1334\"\u003e\n\u003cp data-start=\"1288\" data-end=\"1334\"\u003eepithelial integrity and regenerative balance,\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1335\" data-end=\"1387\"\u003e\n\u003cp data-start=\"1337\" data-end=\"1387\"\u003einflammatory tone in airway-relevant immune cells,\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1388\" data-end=\"1475\"\u003e\n\u003cp data-start=\"1390\" data-end=\"1475\"\u003eoxidative stress\/antioxidant programs (mostly hypothesis-level in secondary sources).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"1477\" data-end=\"1480\"\u003e\n\u003ch2 data-start=\"1482\" data-end=\"1517\"\u003e3) Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-start=\"1519\" data-end=\"1591\"\u003e3.1 Pharmacodynamics framing (non-receptor, gene-program modulation)\u003c\/h3\u003e\n\u003cp data-start=\"1592\" data-end=\"1740\"\u003eChonluten is \u003cstrong data-start=\"1605\" data-end=\"1612\"\u003enot\u003c\/strong\u003e characterized like a GLP-1 agonist (receptor-defined pharmacology). In the Khavinson framework, short peptides are proposed to:\u003c\/p\u003e\n\u003cul data-start=\"1741\" data-end=\"1926\"\u003e\n\u003cli data-start=\"1741\" data-end=\"1926\"\u003e\n\u003cp data-start=\"1743\" data-end=\"1926\"\u003eaccess the \u003cstrong data-start=\"1754\" data-end=\"1774\"\u003eDNA major groove\u003c\/strong\u003e and interact with base-pair “functional group patterns,” enabling sequence-selective binding and gene regulation. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"1928\" data-end=\"2296\"\u003e\u003cstrong data-start=\"1928\" data-end=\"1949\"\u003eImportant nuance:\u003c\/strong\u003e The DNA-binding discussion is strongest at the \u003cstrong data-start=\"1997\" data-end=\"2012\"\u003eclass level\u003c\/strong\u003e (short peptides broadly), and not all peptides have equally strong empirical binding validation. The most defensible position is that this is a \u003cstrong data-start=\"2157\" data-end=\"2188\"\u003eplausible mechanistic model\u003c\/strong\u003e used to explain observed transcriptional effects in related peptides. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-start=\"2298\" data-end=\"2371\"\u003e3.2 Immune\/inflammation cellular effects (direct human-cell evidence)\u003c\/h3\u003e\n\u003cp data-start=\"2372\" data-end=\"2642\"\u003eA 2022 in-vitro study evaluated several Khavinson peptides—including \u003cstrong data-start=\"2441\" data-end=\"2465\"\u003eChonluten tripeptide\u003c\/strong\u003e—in \u003cstrong data-start=\"2469\" data-end=\"2500\"\u003ehuman monocytic THP-1 cells\u003c\/strong\u003e differentiated toward macrophage-like phenotypes, focusing on inflammatory and proliferative processes. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"2644\" data-end=\"2849\"\u003e\u003cstrong data-start=\"2644\" data-end=\"2665\"\u003eWhy this matters:\u003c\/strong\u003e It provides a more contemporary, standardized \u003cstrong data-start=\"2712\" data-end=\"2731\"\u003ehuman cell-line\u003c\/strong\u003e context for claims about inflammatory modulation—though it remains an in-vitro model, not a clinical outcome dataset.\u003c\/p\u003e\n\u003ch3 data-start=\"2851\" data-end=\"2901\"\u003e3.3 Downstream biology map (evidence-weighted)\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"2902\" data-end=\"3516\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"2902\" data-end=\"2961\"\u003e\n\u003ctr data-start=\"2902\" data-end=\"2961\"\u003e\n\u003cth data-start=\"2902\" data-end=\"2911\" data-col-size=\"md\"\u003eDOMAIN\u003c\/th\u003e\n\u003cth data-start=\"2911\" data-end=\"2941\" data-col-size=\"md\"\u003eREPORTED \/ PROPOSED OUTCOME\u003c\/th\u003e\n\u003cth data-start=\"2941\" data-end=\"2961\" data-col-size=\"md\"\u003eEVIDENCE CONTEXT\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"2976\" data-end=\"3516\"\u003e\n\u003ctr data-start=\"2976\" data-end=\"3155\"\u003e\n\u003ctd data-start=\"2976\" data-end=\"3024\" data-col-size=\"md\"\u003eInflammatory signaling in innate immune cells\u003c\/td\u003e\n\u003ctd data-start=\"3024\" data-end=\"3077\" data-col-size=\"md\"\u003emodulation of inflammatory\/proliferative processes\u003c\/td\u003e\n\u003ctd data-start=\"3077\" data-end=\"3155\" data-col-size=\"md\"\u003eTHP-1 macrophage-like in-vitro study \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3156\" data-end=\"3341\"\u003e\n\u003ctd data-start=\"3156\" data-end=\"3193\" data-col-size=\"md\"\u003eAirway\/lung epithelial homeostasis\u003c\/td\u003e\n\u003ctd data-start=\"3193\" data-end=\"3250\" data-col-size=\"md\"\u003e“normalization” of bronchial mucosa function (claimed)\u003c\/td\u003e\n\u003ctd data-start=\"3250\" data-end=\"3341\" data-col-size=\"md\"\u003emainly brochure\/vendor positioning, not RCT-grade \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3342\" data-end=\"3516\"\u003e\n\u003ctd data-start=\"3342\" data-end=\"3385\" data-col-size=\"md\"\u003eGene-expression regulation (class-level)\u003c\/td\u003e\n\u003ctd data-start=\"3385\" data-end=\"3444\" data-col-size=\"md\"\u003eshort peptides can interact with DNA major groove motifs\u003c\/td\u003e\n\u003ctd data-start=\"3444\" data-end=\"3516\" data-col-size=\"md\"\u003emechanistic PDF + class review \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3518\" data-end=\"3521\"\u003e\n\u003ch2 data-start=\"3523\" data-end=\"3551\"\u003e4) Chemistry and identity\u003c\/h2\u003e\n\u003cul data-start=\"3552\" data-end=\"3849\"\u003e\n\u003cli data-start=\"3552\" data-end=\"3664\"\u003e\n\u003cp data-start=\"3554\" data-end=\"3664\"\u003e\u003cstrong data-start=\"3554\" data-end=\"3597\"\u003eSequence (research-peptide definition):\u003c\/strong\u003e \u003cstrong data-start=\"3598\" data-end=\"3624\"\u003eH-Glu-Asp-Gly-OH (EDG)\u003c\/strong\u003e\u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3665\" data-end=\"3849\"\u003e\n\u003cp data-start=\"3667\" data-end=\"3849\"\u003eSome suppliers list a \u003cstrong data-start=\"3689\" data-end=\"3696\"\u003eCAS\u003c\/strong\u003e and formula for EDG\/“T-34” (useful as identity clues, but still not a substitute for COA on the batch you hold). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"3851\" data-end=\"4194\"\u003e\u003cstrong data-start=\"3851\" data-end=\"3917\"\u003eIdentity warning (repeat, because it’s the main failure mode):\u003c\/strong\u003e Capsule products labeled as “AC-7 complex” may list glycine\/glutamic\/aspartic acids as “composition,” which is not the same thing as proving the presence of the \u003cstrong data-start=\"4079\" data-end=\"4106\"\u003especific tripeptide EDG\u003c\/strong\u003e in a defined ratio, purity, and molecular form. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"4196\" data-end=\"4199\"\u003e\n\u003ch2 data-start=\"4201\" data-end=\"4248\"\u003e5) Pharmacokinetics and delivery constraints\u003c\/h2\u003e\n\u003cp data-start=\"4249\" data-end=\"4301\"\u003eThere is \u003cstrong data-start=\"4258\" data-end=\"4286\"\u003eno FDA\/EMA drug-label PK\u003c\/strong\u003e for Chonluten.\u003c\/p\u003e\n\u003cp data-start=\"4303\" data-end=\"4378\"\u003eAs an \u003cstrong data-start=\"4309\" data-end=\"4334\"\u003eunmodified tripeptide\u003c\/strong\u003e, typical translational constraints include:\u003c\/p\u003e\n\u003cul data-start=\"4379\" data-end=\"4593\"\u003e\n\u003cli data-start=\"4379\" data-end=\"4429\"\u003e\n\u003cp data-start=\"4381\" data-end=\"4429\"\u003e\u003cstrong data-start=\"4381\" data-end=\"4402\"\u003erapid proteolysis\u003c\/strong\u003e in vivo (route dependent),\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4430\" data-end=\"4506\"\u003e\n\u003cp data-start=\"4432\" data-end=\"4506\"\u003euncertain systemic and lung-tissue exposure without formal PK\/PD bridging,\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4507\" data-end=\"4593\"\u003e\n\u003cp data-start=\"4509\" data-end=\"4593\"\u003emajor non-equivalence between oral capsules, sublingual drops, and “research vials.”\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"4595\" data-end=\"4767\"\u003eThis is one reason much of the credible discussion stays anchored to \u003cstrong data-start=\"4664\" data-end=\"4679\"\u003ecell models\u003c\/strong\u003e and \u003cstrong data-start=\"4684\" data-end=\"4710\"\u003emechanistic frameworks\u003c\/strong\u003e, rather than claiming established clinical pharmacology.\u003c\/p\u003e\n\u003chr data-start=\"4769\" data-end=\"4772\"\u003e\n\u003ch2 data-start=\"4774\" data-end=\"4793\"\u003e6) Evidence base\u003c\/h2\u003e\n\u003ch3 data-start=\"4795\" data-end=\"4841\"\u003e6.1 Stronger evidence (still non-clinical)\u003c\/h3\u003e\n\u003cul data-start=\"4842\" data-end=\"5195\"\u003e\n\u003cli data-start=\"4842\" data-end=\"5032\"\u003e\n\u003cp data-start=\"4844\" data-end=\"5032\"\u003e\u003cstrong data-start=\"4844\" data-end=\"4873\"\u003eHuman cell-line evidence:\u003c\/strong\u003e Chonluten assessed as a regulator of inflammatory\/proliferative processes in THP-1 macrophage-like cells (in vitro). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5033\" data-end=\"5195\"\u003e\n\u003cp data-start=\"5035\" data-end=\"5195\"\u003e\u003cstrong data-start=\"5035\" data-end=\"5061\"\u003eMechanistic framework:\u003c\/strong\u003e short peptides can interact with DNA major-groove motifs; sequence selectivity is proposed. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"5197\" data-end=\"5263\"\u003e6.2 Weaker\/uncertain evidence (clinical claims not drug-grade)\u003c\/h3\u003e\n\u003cul data-start=\"5264\" data-end=\"5524\"\u003e\n\u003cli data-start=\"5264\" data-end=\"5524\"\u003e\n\u003cp data-start=\"5266\" data-end=\"5524\"\u003eMultiple brochures\/retail pages claim symptomatic benefits in chronic respiratory conditions and “normalization” of bronchial mucosa; these are \u003cstrong data-start=\"5410\" data-end=\"5460\"\u003enot presented as transparent randomized trials\u003c\/strong\u003e in the cited materials. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"5526\" data-end=\"5831\"\u003e\u003cstrong data-start=\"5526\" data-end=\"5542\"\u003eBottom line:\u003c\/strong\u003e In the accessible public literature, Chonluten has \u003cstrong data-start=\"5594\" data-end=\"5669\"\u003ebiologically plausible mechanisms and some in-vitro human-cell evidence\u003c\/strong\u003e, but \u003cstrong data-start=\"5675\" data-end=\"5712\"\u003erobust clinical efficacy datasets\u003c\/strong\u003e (spirometry\/COPD endpoints\/exacerbations\/validated asthma control) are not clearly established from the sources above.\u003c\/p\u003e\n\u003chr data-start=\"5833\" data-end=\"5836\"\u003e\n\u003ch2 data-start=\"5838\" data-end=\"5888\"\u003e7) Safety and tolerability (risk-based framing)\u003c\/h2\u003e\n\u003cp data-start=\"5889\" data-end=\"5959\"\u003eBecause Chonluten is generally sold outside regulated drug frameworks:\u003c\/p\u003e\n\u003cul data-start=\"5960\" data-end=\"6294\"\u003e\n\u003cli data-start=\"5960\" data-end=\"6015\"\u003e\n\u003cp data-start=\"5962\" data-end=\"6015\"\u003eNo standardized contraindications\/interactions exist.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6016\" data-end=\"6168\"\u003e\n\u003cp data-start=\"6018\" data-end=\"6168\"\u003eReal-world risk is dominated by \u003cstrong data-start=\"6050\" data-end=\"6079\"\u003eidentity\/purity\/sterility\u003c\/strong\u003e variability across suppliers and formulations. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6169\" data-end=\"6294\"\u003e\n\u003cp data-start=\"6171\" data-end=\"6294\"\u003eAny immune-modulating agent—especially one with unclear exposure—warrants caution in interpretation until properly studied.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6296\" data-end=\"6299\"\u003e\n\u003ch2 data-start=\"6301\" data-end=\"6327\"\u003e8) Regulatory landscape\u003c\/h2\u003e\n\u003cp data-start=\"6328\" data-end=\"6530\"\u003eChonluten is best described as \u003cstrong data-start=\"6359\" data-end=\"6422\"\u003einvestigational \/ research \/ supplement-market bioregulator\u003c\/strong\u003e, not an FDA\/EMA-approved therapeutic with standardized indications. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"6532\" data-end=\"6535\"\u003e\n\u003ch2 data-start=\"6537\" data-end=\"6607\"\u003e9) Future directions (what would validate Chonluten scientifically)\u003c\/h2\u003e\n\u003col data-start=\"6608\" data-end=\"7239\"\u003e\n\u003cli data-start=\"6608\" data-end=\"6722\"\u003e\n\u003cp data-start=\"6611\" data-end=\"6722\"\u003e\u003cstrong data-start=\"6611\" data-end=\"6640\"\u003eCompound standardization:\u003c\/strong\u003e confirm EDG identity and purity in marketed formats (COA + MS\/HPLC; stability).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6723\" data-end=\"6875\"\u003e\n\u003cp data-start=\"6726\" data-end=\"6875\"\u003e\u003cstrong data-start=\"6726\" data-end=\"6751\"\u003eHuman PK\/PD bridging:\u003c\/strong\u003e demonstrate exposure and a reproducible biomarker signature (e.g., airway inflammatory markers, transcriptomic PD panel).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6876\" data-end=\"7072\"\u003e\n\u003cp data-start=\"6879\" data-end=\"7072\"\u003e\u003cstrong data-start=\"6879\" data-end=\"6904\"\u003eMechanism resolution:\u003c\/strong\u003e define whether EDG directly binds DNA motifs or acts via upstream signaling\/transport pathways in relevant lung\/immune cells. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7073\" data-end=\"7239\"\u003e\n\u003cp data-start=\"7076\" data-end=\"7239\"\u003e\u003cstrong data-start=\"7076\" data-end=\"7107\"\u003eControlled clinical trials:\u003c\/strong\u003e respiratory endpoints (exacerbations, symptoms\/QoL scales, FeNO, sputum eosinophils\/neutrophils, spirometry) and safety monitoring.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-start=\"7241\" data-end=\"7244\"\u003e\n\u003ch2 data-start=\"7246\" data-end=\"7288\"\u003eSelected references (most load-bearing)\u003c\/h2\u003e\n\u003cul data-start=\"7289\" data-end=\"7812\"\u003e\n\u003cli data-start=\"7289\" data-end=\"7444\"\u003e\n\u003cp data-start=\"7291\" data-end=\"7444\"\u003eChonluten defined as \u003cstrong data-start=\"7312\" data-end=\"7352\"\u003etripeptide EDG from respiratory lung\u003c\/strong\u003e in a human-cell inflammatory\/proliferation study: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7445\" data-end=\"7576\"\u003e\n\u003cp data-start=\"7447\" data-end=\"7576\"\u003eEDG identity details (sequence\/formula\/CAS reported by a supplier referencing PubChem): \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7577\" data-end=\"7692\"\u003e\n\u003cp data-start=\"7579\" data-end=\"7692\"\u003eShort-peptide DNA major-groove interaction framework (mechanistic PDF): \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7693\" data-end=\"7812\"\u003e\n\u003cp data-start=\"7695\" data-end=\"7812\"\u003eExamples of “AC-7 complex” labeling that can confuse identity vs defined EDG\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684838764882,"sku":null,"price":45.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/Chonluten20mg.png?v=1770834791","url":"https:\/\/sciencepeptideslab.com\/products\/chonluten-20mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}